Tumor-associated macrophages: from basic research to clinical application
- PMID: 28241846
- PMCID: PMC5329931
- DOI: 10.1186/s13045-017-0430-2
Tumor-associated macrophages: from basic research to clinical application
Abstract
The fact that various immune cells, including macrophages, can be found in tumor tissues has long been known. With the introduction of concept that macrophages differentiate into a classically or alternatively activated phenotype, the role of tumor-associated macrophages (TAMs) is now beginning to be elucidated. TAMs act as "protumoral macrophages," contributing to disease progression. TAMs can promote initiation and metastasis of tumor cells, inhibit antitumor immune responses mediated by T cells, and stimulate tumor angiogenesis and subsequently tumor progression. As the relationship between TAMs and malignant tumors becomes clearer, TAMs are beginning to be seen as potential biomarkers for diagnosis and prognosis of cancers, as well as therapeutic targets in these cases. In this review, we will discuss the origin, polarization, and role of TAMs in human malignant tumors, as well as how TAMs can be used as diagnostic and prognostic biomarkers and therapeutic targets of cancer in clinics.
Keywords: Biomarker; Protumoral activities; Therapeutic target; Tumor microenvironment; Tumor-associated macrophages (TAMs).
Figures
Similar articles
-
Tumor-associated macrophages, potential targets for cancer treatment.Biomark Res. 2017 Aug 8;5:25. doi: 10.1186/s40364-017-0106-7. eCollection 2017. Biomark Res. 2017. PMID: 28804638 Free PMC article. Review.
-
Clinical significance of macrophage heterogeneity in human malignant tumors.Cancer Sci. 2014 Jan;105(1):1-8. doi: 10.1111/cas.12314. Epub 2013 Nov 29. Cancer Sci. 2014. PMID: 24168081 Free PMC article. Review.
-
The role of tumor-associated macrophage in breast cancer biology.Histol Histopathol. 2018 Feb;33(2):133-145. doi: 10.14670/HH-11-916. Epub 2017 Jul 6. Histol Histopathol. 2018. PMID: 28681373 Review.
-
Tumor-associated macrophages: role in cancer development and therapeutic implications.Cell Oncol (Dordr). 2019 Oct;42(5):591-608. doi: 10.1007/s13402-019-00453-z. Epub 2019 May 29. Cell Oncol (Dordr). 2019. PMID: 31144271 Review.
-
Tumor-Associated Macrophages as Target for Antitumor Therapy.Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):97-111. doi: 10.1007/s00005-017-0480-8. Epub 2017 Jun 28. Arch Immunol Ther Exp (Warsz). 2018. PMID: 28660349 Free PMC article. Review.
Cited by
-
The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential.Eur J Med Res. 2024 Oct 5;29(1):490. doi: 10.1186/s40001-024-02073-2. Eur J Med Res. 2024. PMID: 39369212 Free PMC article. Review.
-
Vitamin D3 reduces the expression of M1 and M2 macrophage markers in breast cancer patients.Sci Rep. 2024 Sep 27;14(1):22126. doi: 10.1038/s41598-024-73152-x. Sci Rep. 2024. PMID: 39333342 Free PMC article.
-
MDM2 inhibitors in cancer immunotherapy: Current status and perspective.Genes Dis. 2024 Mar 28;11(6):101279. doi: 10.1016/j.gendis.2024.101279. eCollection 2024 Nov. Genes Dis. 2024. PMID: 39263534 Free PMC article. Review.
-
Proliferating Cell Nuclear Antigen in the Era of Oncolytic Virotherapy.Viruses. 2024 Aug 7;16(8):1264. doi: 10.3390/v16081264. Viruses. 2024. PMID: 39205238 Free PMC article. Review.
-
Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials